2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Détails
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_EF7F13CAC757
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Périodique
Annals of Oncology
Collaborateur⸱rice⸱s
Panel Members
Contributeur⸱rice⸱s
Stahel R., Felip E., Peters S., Kerr K., Besse B., Vansteenkiste J., Eberhardt W., Edelman M., Mok T., O'Byrne K., Novello S., Bubendorf L., Marchetti A., Baas P., Reck M., Syrigos K., Paz-Ares L., Smit EF., Meldgaard P., Adjei A., Nicolson M., Crinò L., Van Schil P., Senan S., Faivre-Finn C., Rocco G., Veronesi G., Douillard JY., Lim E., Dooms C., Weder W., De Ruysscher D., Le Pechoux C., De Leyn P., Westeel V.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Statut éditorial
Publié
Date de publication
2014
Volume
25
Numéro
8
Pages
1475-1484
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on first line/second and further lines of treatment in advanced disease.
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/09/2014 18:10
Dernière modification de la notice
14/02/2022 8:57
Données d'usage
